Centre could exclude low-cost meds, rare disease drugs from trade margin rationalisation

The confusion over which diseases are to be considered as “rare” and which drugs as “orphan” (used to treat rare diseases) has led to the decision of keeping them out of the ambit TMR as of now, people in the know told ET.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/eCuWYbk
via IFTTT